

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and they are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

amivantamab	0 In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
Rybrevant®			
SMC2878			
axicabtagene ciloleucel	0 Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
Yescarta®			
SMC2695			
belantamab mafodotin	0 in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	08/12/2025
Blenrep			
SMC2727			
Bevacizumab in combination with fluoropyrimidine-based chemotherapy	0 Second-line treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy	Routinely available in line with local or regional guidance	08/12/2025
NCMAG124			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Bevacizumab in combination with fluoropyrimidine-based chemotherapy NCMAG 123	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first line treatment of adult patients with metastatic carcinoma of the colon or rectum. On-label use and off-patent medicine. 0	Routinely available in line with local or regional guidance	08/12/2025
blinatumomab Blinicyto® SMC2808	Treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase. 0	Routinely available in line with local or regional guidance	08/12/2025
budesonide Budenofalk® SMC2855	Short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients. 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. 0	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
delgocitinib Anzupgo® SMC2817	0 Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
durvalumab Imfinzi SMC2797	0 in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: •durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) •durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
durvalumab Imfinzi® SMC2857	0 In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
elacestrant Korserdu® SMC2807	0 Monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.	Not routinely available as not recommended for use in NHSScotland	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
eplontersen Wainzua® SMC2755	0 Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	08/12/2025
fruquintinib Fruzaqla SMC2858	0 treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy	Routinely available in line with local or regional guidance	08/12/2025
futibatinib Lytgobi® SMC2661	0 Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Routinely available in line with local or regional guidance	08/12/2025
givinostat Duvyzat® SMC2856	0 Treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
guselkumab Tremfya® SMC2848	0 Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
guselkumab Tremfya® SMC2850	0 Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
iptacopan Fabhalta® SMC2889	0 Treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated.	Not routinely available as not recommended for use in NHSScotland	08/12/2025
isatuximab Sarclisa® SMC2804	0 In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
leniolisib Joenja® SMC2836	0 Treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Routinely available in line with national guidance	08/12/2025
maralixibat Livmarli® SMC2806	0 Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
melatonin MR Slenyto® SMC2882	0 Treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.	Not routinely available as not recommended for use in NHSScotland	08/12/2025
mercaptamine Procysbi® SMC2824	0 Treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	Routinely available in line with national guidance	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
osimertinib Tagrisso® SMC2736	In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	Routinely available in line with local or regional guidance	08/12/2025
progesterone Prometrium® SMC2869	Prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
ribociclib Kisqali® SMC2803	In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
ripretinib Qinlock® SMC2821	Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Routinely available in line with local or regional guidance	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
rucaparib Rubraca® SMC2799	0 Monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Routinely available in line with local or regional guidance	08/12/2025
Semaglutide Wegovy SMC2497	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥30kg/m ² (obesity), or • ≥27kg/m ² to <30kg/m ² (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025
tarlatamab Imdylltra® SMC2816	0 Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.	Not routinely available as not recommended for use in NHSScotland	08/12/2025
tirzepatide Mounjaro® SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m ² (obesity) or ≥27 kg/m ² to <30 kg/m ² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 16/02/2026	08/12/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
trastuzumab Enhertu® SMC2888	treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2- low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.	Not routinely available as not recommended for use in NHSScotland	08/12/2025
zanubrutinib Brukinsa® SMC2819	Monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	Routinely available in line with local or regional guidance	08/12/2025